Abstract
It is generally thought that future advances in the treatment and cure of breast cancer patients will be made possible through a deeper understanding of tumor biology and an improved capability to define the prognosis of each single patient. This will lead to the formulation of new, more selective, and patient-tailored therapies. It is therefore important, when studying potential prognostic factors, to follow methodologic requirements and guidelines which involve the carrying out of prospective studies as confirmatory steps. Repeatedly or recently investigated prognostic markers (tumor size, menopausal status, ER, PgR, 3H thymidine labeling index, c-erbB-2 and p27 expression) were evaluated on a series of 286 prospectively recruited node negative breast cancer patients who underwent loco-regional treatment alone and were closely followed. The individual and relative prognostic contribution of each variable with respect to other factors, as well as their ability to identify node negative patients at risk, were assessed by univariate and multivariate analysis. At a five-year follow-up, only tumor size (p = 0.021) and TLI (p = 0.016) individually proved to be significant prognostic indicators of relapse-free survival. Conversely, p27 expression was not related to RFS and c-erbB-2 expression appeared to have only a short-term effect on patient prognosis. TLI and tumor size, tested in multivariate analysis along with ER and menopausal status, maintained their independent prognostic relevance. The study, performed on a large series of node-negative patients given loco-regional treatment alone, for the first time prospectively recruited, showed the prognostic relevance of TLI and its independence from other clinico-pathologic and biologic factors over a five-year period.
Similar content being viewed by others
References
Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Gass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of finding from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14: 1982–1992, 1996
Zambetti M, Valagussa P, Bonadonna G: Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Ann Oncol 7: 481–485, 1996
The Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320: 491–496, 1989
Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, Cooper MR, Falkson G: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med 320: 485–490, 1989
Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239–257, 1972
Fraser A, Evan G: A licence to kill. Cell 85: 781–784, 1996
Salvesen G, Dixit VM: Caspases: intracellular signaling by proteolysis. Cell 91: 443–446, 1997
Folkman J: What is the evidence that tumors are angiogenesis dependent? J Nat Cancer Inst 82(1): 4–6, 1990
Folkman J: Angiogenesis and breast cancer. J Clin Oncol 12(3): 441–443, 1994
Zhou P, JiangW, Weghorst CM, Weinstein IB: Overexpression of cyclin D1 enhances gene amplification. Cancer Res 56(1): 36–39, 1996
King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB related gene in a human mammary carcinoma. Science 229: 974–976, 1985
Akijama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644–1646, 1986
KrausMH, IssingW, Miki T, Popescu NC, Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci 86: 9193–9197, 1989
Klÿn JGM, Berns PMJJ, Schmitz PIM, Foekeus JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13: 156–170, 1992
Gullick WJ, Srinivasan R: The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat 52: 43–53, 1998
Stephens RW, Brünner N, Jänicke F, Schmitt M: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 52: 99–111, 1998
Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene (Review article). Nature 351: 453–456, 1991
Chang F, Syrjanen S, Syrjanen K: Implication of the p53 tumor suppressor gene in clinical oncology. J Clin Oncol 13: 1009–1022, 1995
Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in node-negative breast cancers. J Nat Cancer Inst 85: 965–970, 1993
Silvestrini R, Daidone MG, Del Bino G, Mastore M, Di Fronzo G, Boracchi P: Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol 4: 213–219, 1993
Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of labeling index versus estrogen receptors and tumor size in nodenegative breast cancer. Breast Cancer Res Treat 7: 161–169, 1986
Silvestrini R, Daidone MG, Mastore M, Di Fronzo G, Coradini D, Boracchi P, Squicciarini P, Salvadori B, Veronesi U: Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol 11: 1150–1155, 1993
Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Squicciarini P, Orefice S, Salvadori B: 3Hthymidine labeling index as a prognostic indicator in nodepositive breast cancer. J Clin Oncol 8: 1321–1326, 1990
Silvestrini R, The SICCAB Group for quality control of cell kinetic determination: Feasibility and reproducibility of the 3H-TdR labeling index in breast cancer. Cell Prolif 21: 437–445, 1991
Piffanelli A, Pellizzola D, Giovannini G, Catozzi L, Faggioli L, Giganti M: Characterization of laboratory working standards for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation of breast cancer biopsies. Tumori 75: 550–556, 1989
Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 53: 457–481, 1958
Cox DR: Regression models and life tables. J Roy Stat Soc 34: 187–220, 1972
Lawless JS: Statistical models and methods for life-time data. Wiley, New York, 1982
SAS Institute Inc: SAS/STAT User's Guide, version 6, 4th ed., vol. 1. Cary, NC: SAS Institute, 1989
Gentili C, Sanfilippo O, Silvestrini R: Cell proliferation in relation to clinical features and relapse in breast cancers. Cancer 48: 974–979, 1981
Silvestrini R, Daidone MG, Luisi A, Mastore M, Leutner, Salvadori B: Cell proliferation in 3800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index. Int J Cancer 74: 122–127, 1997
Tubiana M, Pejovic MH, Chavandra G, Contesso G, Malaise EP: The long term prognostic significance of the thymidine labeling index in breast cancer. Int J Cancer 33: 441–445, 1984
Meyer JS, Friedman E, Mc Crote MM, Bauer WC: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51: 1879–1886, 1983
Hery M, Gioanni J, Lalanne CM, Namer M, Coudri A: The DNA labeling index: a prognostic factor in node-negative breast cancer. Breast Cancer Res Treat 9: 207–212, 1987
Meyer JS, Province M: Proliferative index of breast cancer by thymidine labeling index: prognostic power independent of stage, estrogen and progesteron receptors. Breast Cancer Res Treat 12: 191–199, 1988
Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G: Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25: 1165–1171, 1989
Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of labeling index versus estrogen receptors and tumor size in nodenegative breast cancer. Breast Cancer Res Treat 7: 161–169, 1986
Mangia A, Picciarello M, Tommasi S, Simone G, Barletta A, Longo S, De liso M, D'Errico D, Schittulli F, Catino AM, Paradiso A, De Lena M: Fattori prognostici nel carcinoma della mammella operabile N-: attività proliferativa e caratteristiche clinico-patologiche. Folia Oncologica 14: 247–253, 1991
Tubiana M, Pejovic MH, Koscienly S, Chavandra N, Malaise E: Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer 44: 17–22, 1987
Silvestrini R, Daidone MG, Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56: 1982–1987, 1985
Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Veronesi U: Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13: 697–704, 1995
Révillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791–808, 1998
Kallionemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor-long term survival in breast cancer. Int J Cancer 49: 650–655, 1991
Wiltschke C, Kindas-Muegge I, Steininger A, Reiner A, Reiner G, Preis PN: Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J Cancer Res Clin Oncol 120: 737–742, 1994
Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard S, Pierotti MA, Testori A: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44–49, 1991
Delarue JC, Terrier P, Terrier-Lacombe MJ, Mouriesse H, Gotteland M, May-Levin F: Combined overexpression of cerbB-2 protein and epidermal growth factor receptor (EGR-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study. Bull Cancer 81: 1067–1077, 1994
De Potter CR, Beghin C, Makar AP, Vandekerckhove D, Roels HJ: The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients. Int J Cancer 45: 55–58, 1990
O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA: The relationship between cerbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63: 444–446, 1991
Kommos F, Colley M, Hart CE, Franklin WA: In situ distrubution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-β-subunit. Mol Cell Probes 4: 11–23, 1990
Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, Gullick WJ, Elston CW, Blaney RW: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439–443, 1991
Hartmann LC, Ingle JN, Wold LE, Farr GH Jr, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC: Prognostic value of c-erbB-2 overexpression in axillary lymph node positive breast cancer. tiResults from a randomized adjuvant treatment protocol. Cancer 74: 2956–2963, 1994
Barnes DM, Meyer JS, Gonzalez JG, Gullick WJ, Millis RR: Relationship between c-erbB-2 immunoreactivity and thymidine labeling index in breast carcinoma in situ. Breast Cancer Res Treat 18: 11–17, 1991
Contegiacomo A, Pizzi C, De Marchis L, Alimandi M, Delrio P, Di Palma E, Petrella G, Ottini L, French D, Frati L, Bianco AR, Mariani-Costantini R: High cell kinetics is associated with amplification of the int-2, bcl-1, myc and erbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers. Int J Cancer 61(1): 1–6, 1995
Slamon DJ, Godolphin W, Jones LA Holt JA, Wong SG, Keith DE, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989
Thor AD, Schwartz LH, Koerner FC Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Paniali DL, Marks PJ, Fingert HJ, et al.: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49: 7147–7152, 1989
Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn H-J for the International (Ludwig) Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049–1056, 1992
Gasparini G, Widner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12: 454–466, 1994
Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-posivite early breast cancer. N Engl J Med 330: 1260–1266, 1994
Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, Mc Guire WL: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599–605, 1992
Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver KL, Hurd SD, Stewart SJ: p185 c-erbB-2 signalling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54: 3758–3765, 1994
Baselga J, Seidman AD, Rosen PP, Norton L: HER2 overexpression and paclitaxel sensitivity in breast cancer; therapeutic implications. Oncology (Huntingt) 11(Suppl 2): 43–48, 1997
Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129–1135, 1995
Stål O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, Nordenskjold B: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A: 185–190, 1995
Tan P, Cady B, WannerM, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res 57: 1259–1263, 1997
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227–230, 1997
Wu J, Shen Z-Z, Jiang M, Han Q-N, Fontana JA, Barsky SH Shao ZM: Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br J Cancer 79: 1572–1578, 1999
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nat Med 2: 222–225, 1997
Reed W, Florenes WA, Holm R, Hannisdal E, Nesland JN: Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch 435: 116–124, 1999
Sulkes A, Livingstone RB, Murphy WK: Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 62: 513–515, 1979
Daidone MG, Silvestrini R, Canova S, Valagussa P: Tumor cell kinetics and course of node-positive (N+) breast cancer (Abstract). Proc Am Soc Clin Oncol 8: 24, 1989
Zambetti M, Bonadonna G, Valagussa P, Daidone MG, Coradini D, Bignami P, Contesso G, Silvestrini R: Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer. NCI Monograph 11: 77–83, 1992
Gardin G, Alama A, Rosso R, Campora E, Repetto L, Pronzato P, Merlini L, Naso C, Camoriano A, Meazza R: Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res Treat 32: 311–318, 1994
Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A, Casadei Giunchi D, Vio A, Saragoni A, Silvestrini R: Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 43: 7–14, 1997
Rights and permissions
About this article
Cite this article
Volpi, A., Paola, F.D., Nanni, O. et al. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 63, 181–192 (2000). https://doi.org/10.1023/A:1006464426977
Issue Date:
DOI: https://doi.org/10.1023/A:1006464426977